• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by R. Paul Hansen

    4/1/21 6:55:05 PM ET
    $CGIX
    Medical Specialities
    Health Care
    Get the next $CGIX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hansen Paul R.

    (Last) (First) (Middle)
    C/O VYANT BIO, INC. 2 EXECUTIVE CAMPUS
    2370 STATE ROUTE 70, SUITE 310

    (Street)
    CHERRY HILL NJ 08002

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/30/2021
    3. Issuer Name and Ticker or Trading Symbol
    Vyant Bio, Inc. [ VYNT ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24: Power of Attorney
    No securities are beneficially owned.
    /s/ John A. Roberts, attorney-in-fact 04/01/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CGIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CGIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:48:08 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Marcus Boehm

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:46:47 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Joanna Horobin

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:32:36 PM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    SEC Filings

    View All

    SEC Form 3 filed by Cancer Genetics, Inc.

    3 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 7:03:48 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Cancer Genetics, Inc.

    10-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/31/21 6:01:06 AM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Cancer Genetics, Inc.

    8-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/25/21 9:17:14 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Genetics and StemoniX Announce Merger Closing

    Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of t

    3/31/21 6:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

    Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Commo

    3/25/21 9:15:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed

    SC 13D - CANCER GENETICS, INC (0001349929) (Subject)

    2/25/21 3:05:43 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:43:25 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:26:44 PM ET
    $CGIX
    Medical Specialities
    Health Care